HBW Advisory Services LLC Buys 925 Shares of Amgen Inc. (NASDAQ:AMGN)

HBW Advisory Services LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.8% in the first quarter, HoldingsChannel.com reports. The fund owned 9,484 shares of the medical research company’s stock after acquiring an additional 925 shares during the quarter. HBW Advisory Services LLC’s holdings in Amgen were worth $2,955,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of AMGN. Capital World Investors lifted its position in Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after purchasing an additional 6,029,058 shares during the period. Norges Bank bought a new position in Amgen in the 4th quarter valued at about $1,541,991,000. GAMMA Investing LLC raised its position in shares of Amgen by 43,573.5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock valued at $1,140,768,000 after buying an additional 3,653,205 shares in the last quarter. Capital International Investors lifted its holdings in shares of Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after acquiring an additional 3,495,503 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMGN has been the subject of several research analyst reports. Citigroup restated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Royal Bank of Canada decreased their price target on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. UBS Group restated a “neutral” rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Finally, Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $309.22.

Amgen Trading Up 0.1%

Shares of NASDAQ AMGN opened at $288.47 on Tuesday. The firm has a 50 day moving average price of $283.12 and a two-hundred day moving average price of $285.27. The stock has a market cap of $155.11 billion, a P/E ratio of 38.21, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.96 earnings per share. As a group, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.